The Indian Pharmaceutical Association (IPA) will organise a Symposium on Nasal and Pulmonary Drug Delivery in Mumbai from October 24 to 25, 2013. The event is the sixth in the series of similar programmes organised over the last decade. This year the theme of the symposium is ‘Global Regulatory Trends.’
The USP of the symposium will be the workshops organised on day two, which will give the participants an opportunity for closer interaction and hands-on experience. The symposium will have an exhibition by sponsors and poster presentations by leading researchers from India and abroad, working in the area of nasal and pulmonary drug delivery.
Aptar Pharma has continued to be the platinum partner and co-organiser for the event since the beginning. Mexichem Fluor, DH Industries, Presspart, Malvern AIMIL, Innova Systems, Copley Scientific have been the gold partners. This year, IPA has added two more gold partners, Team Consulting and DFE Pharma for the event.
Experts would share their knowledge in this field with topics like: ‘Overview of the Ph. Eur’ – Dr Steven Nichols; ‘Methodologies for In-Vitro Bioequivalence Testing of Generic Inhaled Products in the Emerging Markets’ – Mark Copley, Copley Scientific; ‘The HFA Challenge: The Safe, Effective Containment and Delivery of pMDI Respiratory Medicines’ – Richard Turner, Presspart; ‘pMDI Filling and Control Equipment Solutions to Meet the Ever Increasing Demands of the Global Regulatory Authorities’ – Paul Sullivan, DH Industries; ‘Automated Testing of Nasal Sprays and Metered Dose Inhalers and FDA Regulatory Requirements’ – HenrikKrarup, Innova Systems; ‘Time for Change: Patient Choice and Improving Compliance’ – David Harris, Team Consulting; Global Bioequivalence Expectations for Orally Inhaled and Nasal Drug Products’ – Dr Julie Suman, Nextbreath; ‘Challenges and Opportunities in Dry Powder Inhalers’ – Dr Kapileshwar Swain, Wockhardt; ‘Utilising QbD Analytical Method Development in Nasal Spray Droplet Size Characterisation’ – Stuart Wakefield, Malvern AIMIL; ‘Medical Propellants: Regulatory Update and Other News’ – Dr Tim Noakes, Mexichem; ‘Inhaled Therapies for Tuberculosis in the Russian Regulatory Landscape’ – Dr Amit Misra, CDRI.
Three parallel workshops will be conducted in the first half of day two by Malvern AIMIL, Innova Systems and Aptar Pharma.
IPA plans to bring in experts from US FDA, EDQM and DCGI office to participate in this programme. The media partner for the event is Express Pharma.
The first edition of the symposium was organised way back in 1999, followed by the next one in 2004, the third in 2007, fourth in 2009 and the fifth in 2011. The earlier editions of the symposium were focussed on discussing the basics of formulation technology and manufacture of nasal and pulmonary drug delivery systems. Keeping in view the interest shown by the Indian pharma companies for making forays into the regulated markets, in 2009, IPA had decided to focus on the basics of regulatory filing concerning these delivery systems. In 2011, IPA took the theme a step forward by focussing on the regulatory challenges faced by the pharma companies working on nasal and pulmonary drug delivery systems.
EP News Bureau – Mumbai